Did You Know?
Many pharmaceutical companies are realizing the benefits of DMS technology as it reduces a product's time to market by streamlining pre-clinical, clinical, commercialization and post-market phase documentation and by simultaneously reducing the cost associated with document administration and compliance.
The IND is the focus of the preclinical phase and is often the final result of information recorded on thousands of documents. The preclinical phase can last up to several years so information can become voluminous. A document control system allows professionals to collaborate, route and approve documentation along various routes and with full version control. A document control system also allows professionals to stay within the limits of 21 CFR Part 58, 21 CFR Part 312 and 21 CFR 312 regulations.
To read more about the benefits of document control management during clinical, commercialization and post-market phases in pharmaceutical environments please download the following: